T-VEC at antigen release, addressing threshold drift
T-VEC (oncolytic lysis with GM CSF) acts at the antigen release step of the cancer-immunity cycle. The failure mode is threshold drift: threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the antigen release step of the cancer-immunity cycle (capacitor regime, position P1), T-VEC acts via oncolytic lysis with GM CSF. The failure mode is threshold drift: threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation. The intervention's regime-type class lines up with the position's regime, and failure_threshold_drift belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p1
- Failure modes
- failure_threshold_drift
Evidence at generation
"t-vec" AND "cancer immunotherapy"
- PMID 30643254
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
- PMID 33803762
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma.
- PMID 26488034
Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
- PMID 30832995
Cancer Vaccines.
- PMID 40043281
Melanoma neoadjuvant treatment: review and update of recent trials.
Targets: —
Not found in ChEMBL: T-VEC (talimogene laherparepvec)
t-vec cancer immunotherapy
- NCT01740297
Melanoma
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities
- NCT04163952
Locally Advanced Skin Squamous Cell Carcinoma
Primary: Number of Participants With Treatment Related Adverse Events as Assessed by CTCAE v4.0
- NCT03300544
Locally Advanced Rectal Adenocarcinoma
Primary: Determination of Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) of Talimogene Laherparepvec in Combination With Chemotherapy and Radiation in Rectal Cancer.
- NCT03842943
Cutaneous Melanoma
Primary: Pathologic Complete Response
- NCT03071094
Hepatocellular Carcinoma (HCC)
Primary: Phase I: Number of Participants With Dose Limiting Toxicities (DLTs)
Status timeline
- Draft2026-05-30T11:27:14Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system